周六报道，Anito-Cel在iMMagine-1复发性/难治性多发性骨髓瘤中证明了96%的ORR和74%的CR/sCR，支持计划的2026年商业发布

2025-12-08 16:47

Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time --
Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at 10-5 sensitivity level --
12-month PFS and OS rates were 82.1% and 94.0%; 18-month PFS and OS rates were 67.4% and 88.0%; 24-month PFS and OS rates were 61.7% and 83.0% --
To date, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune effector cell-associated enterocolitis have been observed with anito-cel to date; all patients were dosed at least 12 months ago --
The company reiterates its planned 2026 commercial launch --
iMMagine-1 data to be presented during an oral presentation at the ASH Annual Meeting on Saturday, December 6, 2025 --
Company to host a live webcast event with an expert panel of clinicians during ASH --